Both drugs can have more serious side effects, such as pancreatitis and allergic reactions, though these are not as common
100-250 mcg/da o 1.000 mcg das alternos, 1-2 sem, luego, 250-1.000 mcg/mes hasta remisin, o bien: 1.000 mcg/da (1 sem), 1.000 mcg/sem (4-8 sem), 1.000 mcg/mes
Farmacodinamia: Propiedades farmacodinmicas: Clase farmacolgica agonista del receptor del pptido similar al glucagn tipo 1 (GLP-1 por sus siglas en ingls)
No significant difference in dementia risk was observed between SGLT2 inhibitors versus GLP1 receptor agonists
Condensation risk : When moving peptides from fridge to room temp, condensation can form
More than three cardiovascular risk factors without established CVD or CKD: Weak recommendation for starting SGLT-2 inhibitors and weak against starting GLP-1 receptor agonists